Table 3.
Three‐ and five‐year absolute risks of CIN3 and CIN2+, after one, two and three negative cotests, adjusted for unresolved positive results
| n | 3‐year risk of CIN3 | 5‐year risk of CIN3 | 3‐year risk of CIN2+ | 5‐year risk of CIN2+ | |||||
|---|---|---|---|---|---|---|---|---|---|
| Absolute risk | 95% CI | Absolute risk | 95% CI | Absolute risk | 95% CI | Absolute risk | 95% CI | ||
| One negative cotest | 174,205 | 0.025% | (0.014, 0.036) | 0.034% | (0.023, 0.046) | 0.061% | (0.037, 0.085) | 0.128% | (0.101, 0.155) |
| Two negative cotests | 63,813 | 0.010% | (0.000, 0.025) | 0.041% | (0.007, 0.076) | 0.040% | (0.019, 0.062) | 0.092% | (0.045, 0.139) |
| Three negative cotests1 | 10,549 | 0.016% | (0.000, 0.052) | 0.016% | (0.000, 0.052) | 0.016% | (0.000, 0.052) | 0.016% | (0.000, 0.052) |
Assuming women with unresolved positive results are missing at random given their positive result, see Supporting Information Material 2 for details. Confidence intervals are based on bootstrapping. No women were diagnosed with invasive cervical cancer.
1
Based on one observed event.